(Q45095311)

English

Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma

scientific article published in November 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma (English)

1 reference

Europe PubMed Central

9 December 2017

author name string

Albrecht Reichle

1

1 reference

Europe PubMed Central

9 December 2017

Klaus Bross

2

1 reference

Europe PubMed Central

9 December 2017

Thomas Vogt

3

1 reference

Europe PubMed Central

9 December 2017

Frauke Bataille

4

1 reference

Europe PubMed Central

9 December 2017

Peter Wild

5

1 reference

Europe PubMed Central

9 December 2017

Anna Berand

6

1 reference

Europe PubMed Central

9 December 2017

Stefan W Krause

7

1 reference

Europe PubMed Central

9 December 2017

Reinhard Andreesen

8

1 reference

Europe PubMed Central

9 December 2017

language of work or name

0 references

publication date

1 November 2004

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

101

1 reference

Europe PubMed Central

9 December 2017

2247-2256

1 reference

Europe PubMed Central

9 December 2017

10

1 reference

Europe PubMed Central

9 December 2017

Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

21 January 2018

Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

21 January 2018

Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

21 January 2018

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

21 January 2018

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin and the Risk of Colorectal Cancer in Women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

[Stabilizing the course of patients with stage IV advanced malignant melanoma by trofosfamide treatment]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia associated with the production of insulin-like growth factor (IGF)-II by a hemangiopericytoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of C-reactive protein as a prognostic indicator in advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumors and inflammatory infiltrates: friends or foes?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20574

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20574

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45095311&oldid=2065733447"